Into the Labyrinth of the Lipocalin α1-Acid Glycoprotein

被引:22
|
作者
Ruiz, Mario [1 ]
机构
[1] Univ Gothenburg, Dept Chem & Mol Biol, Gothenburg, Sweden
来源
FRONTIERS IN PHYSIOLOGY | 2021年 / 12卷
关键词
alpha 1-acid glycoprotein; orosomucoid; inflammation; metabolism; ligand-binding; Lipocalin; HUMAN ALPHA(1)-ACID GLYCOPROTEIN; ACUTE-PHASE PROTEIN; PLATELET-ACTIVATING-FACTOR; LIGAND-BINDING PROPERTIES; MAIN GENETIC-VARIANTS; TUMOR-NECROSIS-FACTOR; DRUG-BINDING; HUMAN-SERUM; ALPHA1-ACID GLYCOPROTEIN; ENERGY HOMEOSTASIS;
D O I
10.3389/fphys.2021.686251
中图分类号
Q4 [生理学];
学科分类号
071003 ;
摘要
alpha(1)-acid glycoprotein (AGP), also known as Orosomucoid (ORM), belongs to the Lipocalin protein family and it is well-known for being a positive acute-phase protein. AGP is mostly found in plasma, with the liver as main contributor, but it is also expressed in other tissues such as the brain or the adipose tissue. Despite the vast literature on AGP, the physiological functions of the protein remain to be elucidated. A large number of activities mostly related to protection and immune system modulation have been described. Recently created AGP-knockout models have suggested novel physiological roles of AGP, including regulation of metabolism. AGP has an outstanding ability to efficiently bind endogenous and exogenous small molecules that together with the complex and variable glycosylation patterns, determine AGP functions. This review summarizes and discusses the recent findings on AGP structure (including glycans), ligand-binding ability, regulation, and physiological functions of AGP. Moreover, this review explores possible molecular and functional connections between AGP and other members of the Lipocalin protein family.
引用
收藏
页数:10
相关论文
共 50 条
  • [1] α1-acid glycoprotein in shock
    Muchitsch, EM
    Pichler, L
    Schwarz, HP
    [J]. NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 1998, 357 (04) : R113 - R113
  • [2] Contribution of the α1-Acid Glycoprotein in Drug Pharmacokinetics: The Usefulness of α1-Acid Glycoprotein-Knockout Mice
    Nakamura, Yuka
    Watanabe, Hiroshi
    Imafuku, Tadashi
    Fujita, Issei
    Ganaha, Yuto
    Takeo, Toru
    Nakagata, Naomi
    Maeda, Hitoshi
    Maruyama, Toru
    [J]. MOLECULAR PHARMACEUTICS, 2024, 21 (07) : 3144 - 3150
  • [3] α1-acid glycoprotein and multidrug resistance
    Woodcock, BG
    Keese, A
    Harder, S
    Ganser, A
    Abdel-Rahman, MS
    Rietbrock, S
    [J]. DRUG RESISTANCE IN LEUKEMIA AND LYMPHOMA II, 1997, 3 : 435 - 442
  • [4] Binding of imatinib by α1-acid glycoprotein
    Gambacorti-Passerini, C
    le Coutre, P
    Zucchetti, M
    D'Incalci, M
    [J]. BLOOD, 2002, 100 (01) : 367 - 368
  • [5] α1-acid glycoprotein is marker of cancer progression
    Mikhailov, A.
    [J]. FEBS JOURNAL, 2006, 273 : 254 - 255
  • [6] DISULFIDE BONDS OF ALPHA 1-ACID GLYCOPROTEIN
    SCHMID, K
    BURGI, W
    COLLINS, JH
    NANNO, S
    [J]. BIOCHEMISTRY, 1974, 13 (13) : 2694 - 2697
  • [7] Albumin and α1-acid glycoprotein: old acquaintances
    Zemek, Filip
    Korabecny, Jan
    Sepsova, Vendula
    Karasova Zdarova, Jana
    Musilek, Kamil
    Kuca, Kamil
    [J]. EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2013, 9 (08) : 943 - 954
  • [8] Preclinical investigations of α1-acid glycoprotein (orosomucoid)
    Pichler, L
    Muchitsch, EM
    Schwarz, HP
    [J]. WIENER KLINISCHE WOCHENSCHRIFT, 1999, 111 (05) : 192 - 198
  • [9] Saccharide components and the structure of α1-acid glycoprotein
    Tluchorova, S
    Karpenko, V
    Entlicher, G
    [J]. CHEMICAL PAPERS, 1998, 52 : 365 - 365
  • [10] Fibrillation properties of human α1-acid glycoprotein
    Scire, Andrea
    Baldassarre, Maurizio
    Galeazzi, Roberta
    Tanfani, Fabio
    [J]. BIOCHIMIE, 2013, 95 (02) : 158 - 166